Literature DB >> 24535159

Finding suitable targets is the major obstacle to cancer gene therapy.

Steven A Rosenberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24535159      PMCID： PMC6354240          DOI： 10.1038/cgt.2014.3

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN： 0929-1903            Impact factor:   5.987


× No keyword cloud information.
  20 in total

1.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

Authors:  Richard A Morgan; James C Yang; Mio Kitano; Mark E Dudley; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

2.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

3.  Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.

Authors:  Steven A Rosenberg; James C Yang; Richard M Sherry; Udai S Kammula; Marybeth S Hughes; Giao Q Phan; Deborah E Citrin; Nicholas P Restifo; Paul F Robbins; John R Wunderlich; Kathleen E Morton; Carolyn M Laurencot; Seth M Steinberg; Donald E White; Mark E Dudley
Journal:  Clin Cancer Res       Date:  2011-04-15       Impact factor: 12.531

4.  Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice.

Authors:  Dhanalakshmi Chinnasamy; Zhiya Yu; Marc R Theoret; Yangbing Zhao; Rajeev K Shrimali; Richard A Morgan; Steven A Feldman; Nicholas P Restifo; Steven A Rosenberg
Journal:  J Clin Invest       Date:  2010-10-11       Impact factor: 14.808

Review 5.  Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know.

Authors:  Steven A Rosenberg
Journal:  Nat Rev Clin Oncol       Date:  2011-08-02       Impact factor: 66.675

6.  T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

Authors:  Maria R Parkhurst; James C Yang; Russell C Langan; Mark E Dudley; Debbie-Ann N Nathan; Steven A Feldman; Jeremy L Davis; Richard A Morgan; Maria J Merino; Richard M Sherry; Marybeth S Hughes; Udai S Kammula; Giao Q Phan; Ramona M Lim; Stephen A Wank; Nicholas P Restifo; Paul F Robbins; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Mol Ther       Date:  2010-12-14       Impact factor: 11.454

7.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Authors:  James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

8.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.

Authors:  Y Kawakami; S Eliyahu; C H Delgado; P F Robbins; L Rivoltini; S L Topalian; T Miki; S A Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

9.  Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

Authors:  Richard A Morgan; Nachimuthu Chinnasamy; Daniel Abate-Daga; Alena Gros; Paul F Robbins; Zhili Zheng; Mark E Dudley; Steven A Feldman; James C Yang; Richard M Sherry; Giao Q Phan; Marybeth S Hughes; Udai S Kammula; Akemi D Miller; Crystal J Hessman; Ashley A Stewart; Nicholas P Restifo; Martha M Quezado; Meghna Alimchandani; Avi Z Rosenberg; Avindra Nath; Tongguang Wang; Bibiana Bielekova; Simone C Wuest; Nirmala Akula; Francis J McMahon; Susanne Wilde; Barbara Mosetter; Dolores J Schendel; Carolyn M Laurencot; Steven A Rosenberg
Journal:  J Immunother       Date:  2013-02       Impact factor: 4.456

10.  Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia.

Authors:  Eric Tran; Dhanalakshmi Chinnasamy; Zhiya Yu; Richard A Morgan; Chyi-Chia Richard Lee; Nicholas P Restifo; Steven A Rosenberg
Journal:  J Exp Med       Date:  2013-05-27       Impact factor: 14.307
View more
  13 in total

1.  Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model.

Authors:  J Yan; C Tingey; R Lyde; T C Gorham; D K Choo; A Muthumani; D Myles; L P Weiner; K A Kraynyak; E L Reuschel; T H Finkel; J J Kim; N Y Sardesai; K E Ugen; K Muthumani; D B Weiner
Journal:  Cancer Gene Ther       Date:  2014-11-14       Impact factor: 5.987

Review 2.  CD8⁺ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor Activity.

Authors:  G Elizabeth Pluhar; Christopher A Pennell; Michael R Olin
Journal:  Crit Rev Immunol       Date:  2015       Impact factor: 2.214

3.  Genetically engineered lymphocytes and adoptive cell therapy: cancer immunotherapy's smart bombs.

Authors:  S K Libutti
Journal:  Cancer Gene Ther       Date:  2015-03       Impact factor: 5.987

Review 4.  Navigating CAR-T cells through the solid-tumour microenvironment.

Authors:  Andrew J Hou; Laurence C Chen; Yvonne Y Chen
Journal:  Nat Rev Drug Discov       Date:  2021-05-10       Impact factor: 84.694

5.  Modularly Constructed Synthetic Granzyme B Molecule Enables Interrogation of Intracellular Proteases for Targeted Cytotoxicity.

Authors:  Patrick Ho; Christopher Ede; Yvonne Y Chen
Journal:  ACS Synth Biol       Date:  2017-05-22       Impact factor: 5.110

Review 6.  To affinity and beyond: harnessing the T cell receptor for cancer immunotherapy.

Authors:  Jessica E Thaxton; Zihai Li
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

7.  Melanoma Immunotherapy in Mice Using Genetically Engineered Pluripotent Stem Cells.

Authors:  Mohammad Haque; Jianyong Song; Kristin Fino; Praneet Sandhu; Youfei Wang; Bing Ni; Deyu Fang; Jianxun Song
Journal:  Cell Transplant       Date:  2016-01-15       Impact factor: 4.064

8.  Identification of DRG-1 As a Melanoma-Associated Antigen Recognized by CD4+ Th1 Cells.

Authors:  Yukiko Kiniwa; Jiang Li; Mingjun Wang; Chuang Sun; Jeffrey E Lee; Rong-Fu Wang; Helen Y Wang
Journal:  PLoS One       Date:  2015-05-20       Impact factor: 3.240

Review 9.  Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins.

Authors:  Martin C Boonstra; Susanna W L de Geus; Hendrica A J M Prevoo; Lukas J A C Hawinkels; Cornelis J H van de Velde; Peter J K Kuppen; Alexander L Vahrmeijer; Cornelis F M Sier
Journal:  Biomark Cancer       Date:  2016-09-27

10.  The effect of adenosine A1 receptor agonist and antagonist on p53 and caspase 3, 8, and 9 expression and apoptosis rate in MCF-7 breast cancer cell line.

Authors:  Mehdi Nikbakht Dastjerdi; Mohammad Zamani Rarani; Ali Valiani; Mohsen Mahmoudieh
Journal:  Res Pharm Sci       Date:  2016-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.